Betamethasone Oral Solution |
Celestone Syrup |
Clinical Trial: Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section
This study is currently recruiting patients.
Verified by Emory University August 2005
|
Purpose
This is a randomized, multicenter, double blind, placebo controlled trial of betamethasone versus a placebo given prior to the mothers at term and near term gestation (>34-<40 weeks of gestation)who are scheduled to undergo a planned Cesarean section. The study design is to determine the efficacy and safety of betamethasone in the prevention of breathing problems commonly seen in this population.
In infants born by elective Cesarean section, antenatal betamethasone treatment will reduce the risk of NICU admission 11 to 8% and/or oxygen therapy +/- PPV for >30 minutes from 4.5 to 2.5%.
| Condition | Intervention |
|---|---|
| Elective cesarean section Respiratory Distress Syndrome | Drug: Glucocorticoid (betamethasone) |
MedlinePlus related topics: Premature Babies; Respiratory Diseases
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Official Title: Randomized Controlled Trial of Antepartum Betamethasone Treatment for Prevention of Respiratory Distress in Infants Born by Elective Cesarean Section
Expected Total Enrollment: 400
Study start: August 2005; Expected completion: February 2008
Last follow-up: September 2007; Data entry closure: September 2007
The purpose of this pilot study is to determine if antepartum betamethasone given to mothers undergoing elective cesarean section (ECS) delivery at term or near term gestation (>34 and < 40 weeks of gestation) is safe and feasible in reducing neonatal respiratory morbidity and the related admissions to neonatal intensive care units (NICU).
The data from this pilot study will be used to support a NIH application for a multicenter randomized trial to determine, if compared to placebo treatment, antenatal betamethasone initiated 2-7 days prior to an ECS results in decreased occurrence of respiratory morbidity and NICU admissions in the newborn.
The multicenter protocol was recently reviewed by the NICHD network for clinical trial. The reviewers were enthusiastic about the scientific merit and public health importance of the study but asked for a pilot study to determine feasibility before launching the national trial. Given the rise in the rate of CS deliveries, we project substantial health cost savings from this preventive strategy if it were found to be successful in reducing neonatal morbidity.
Eligibility
Accepts Healthy Volunteers
Inclusion Criteria:
- Pregnant women >/= 34 weeks gestation scheduled to undergo operative delivery within 48-72 hours after study enrollment
Exclusion Criteria:
- Known contraindication to the use of betamethasone in the mother
- Known lethal or non-lethal congenital anomaly diagnosed antenatally
- Spontaneous labor
- Premature rupture of membranes
Location and Contact Information
Golde Dudell, M.D. (404)727-8682 gdudell@emory.edu
Georgia
Emory University, Department of Pediatrics, Division of Neonatology, Atlanta, Georgia, 30322, United States; Recruiting
Golde Dudell, M.D. (404)727-8682 gdudell@emory.edu
Golde Dudell, M.D., Sub-Investigator
Lucky Jain, M.D., Principal Investigator, Emory University Department of Pediatrics, Division of Neonatology
More Information
Last Updated: August 30, 2005
Record first received: August 29, 2005
ClinicalTrials.gov Identifier: NCT00139256
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-09-06
Resources
- Betamethasone Oral Solution (Drug Digest)
- Celestone Syrup (Drug Digest)

Not Signed In -

